Thursday, September 26th, 2024

Sime Darby Bhd Capitalizes on Domestic Tailwinds: Strong Growth Ahead

Date: September 25, 2024
Broker: CGS-CIMB Securities Malaysia


Company Overview

Sime Darby Bhd is a diversified Malaysia-based conglomerate involved in various sectors, including industrial, motors, and healthcare. The company is strategically positioned to capitalize on domestic market opportunities while benefiting from international ventures.

Financial Performance and Outlook

CGS-CIMB has maintained an “Add” recommendation for Sime Darby Bhd with an increased target price of RM3.60. The company is expected to see significant growth in its profit before interest and tax (PBIT), driven primarily by contributions from Malaysia-based operations.

Key Drivers for Growth

  • Malaysia-Based Contributions: The contribution of Malaysia-based operations to Sime Darby’s PBIT is projected to increase from 24% in FY23 to 60% by FY25F. This substantial rise is attributed to currency benefits and the full impact of the UMW acquisition.

  • Currency Benefits: While there are some translation impacts from overseas profits due to the strengthening of the Malaysian Ringgit (RM), the company is expected to benefit from currency gains, particularly in its domestic operations.

  • UMW Impact: The acquisition of UMW is expected to further boost earnings, particularly in the automotive sector, helping Sime Darby consolidate its position in the domestic market.

Valuation and Recommendation

Despite the notable benefits from currency gains and the UMW acquisition, Sime Darby Bhd is currently trading at an attractive valuation of just 9.5 times its FY25F price-to-earnings ratio (P/E). The stock also offers a dividend yield of approximately 5%, making it a compelling investment opportunity.

CGS-CIMB reiterates the “Add” recommendation on the stock, supported by strong domestic tailwinds and a positive earnings outlook driven by strategic acquisitions and favorable currency movements.

Hyphens Pharma International – A Healthy Pipeline Driving Revenue Growth and Profitability

Company Highlights: Hyphens Pharma International (HYP) has shown a strong performance in the first half of 2024, achieving record revenue of S$99.6 million, a significant 33.4% year-over-year (YoY) increase. The company’s growth was driven...

JD Health International Inc: Technical Buy with Promising Upside Targets

Date of Report: September 25, 2024Broker: CGS International Securities Stock Overview Company Name: JD Health International IncStock Code: 6618Last Price: 26.75 Investment Recommendation JD Health International Inc is identified as a Technical Buy in...

Bullish Breakout Signals Strong Upside Potential for WCE Holdings

Date: September 18, 2024Broker Name: CGS International Securities Malaysia Sdn. Bhd. Company Overview WCE Holdings Berhad operates as a holding company, primarily focused on designing, constructing, and developing West-Coast Expressway projects in Malaysia. The...